Evidence map›Paper›PMID 42645553›Full record

ReviewBiogerontology2026

An aging essential 8: closing the gap between geroscience and the public it serves.

Franco Grimolizzi

Abstract readReview
In one paragraph

Review in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Franco GrimolizziDivision of Molecular Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. franco.grimolizzi@outlook.it.ORCID https://orcid.org/0000-0002-5783-6875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Longevity science has advanced faster than the public's capacity to interpret it. Biological age tests, longevity clinics, and consumer wearables now reach millions of people, yet no shared framework exists to tell an individual what those numbers mean or what to do about them. Cardiovascular medicine encountered a comparable problem and resolved it not with a new therapeutic but with a communication instrument: Life's Essential 8, which distilled a contested risk landscape into eight components scored from 0 to 100, and which has since been shown to track biological aging itself. This Perspective argues that geroscience has assembled much of the material for an equivalent instrument, even while the field continues to disagree about foundational questions. Expert panels have converged on which biomarkers are worth tracking as outcomes in aging intervention trials, and have concluded that no single biomarker suffices, which leaves a composite as the only viable path. What has not happened is the translation of that research-level agreement into a public-facing instrument. A candidate structure is proposed, comprising four behavioral and four biological pillars with explicit scoring thresholds, designed for administration by clinicians in primary care rather than by longevity clinics only, and constructed so that seven of the eight components require only a questionnaire, a bedside test, and routine bloods.

Indexed as

AgingGeroscienceLongevityBiomarkersHumansBiomarkersAging biomarkersBiological agingComposite health scoreHealth equityHealthy longevityPrimary careRisk communication

Identifiers

PMID42645553
PMCPMC13518415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.